378 results about "Dendrite" patented technology

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

The invention relates to the technical field of cellular immunotherapy, in particular to application of efonidipine in preparation of a dendritic cell immunologic adjuvant. The invention provides an application of efonidipine in preparation of a dendritic cell immunologic adjuvant. It is found that efonidipine can promote maturation, migration and antigen presentation functions of DCs, and the homing ability of DCs and CD8 + T cell activation are remarkably improved. The activation aspect of efonidipine on DCs comprises improvement of expression of maturation indexes CD80, CD40 and CD86, expression of a migration index CCR7, activation of CD8 + T cells by antigen presentation and the like. The efonidipine used in the invention is a drug approved by FDA for clinical treatment of cardiovascular diseases, the application of the efonidipine in immunotherapy is found, new use of old drugs is realized, and the efonidipine has great economic value.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms, and methods of producing and operating the same. In some aspects, an electrochemical cell can include an anode and a cathode material disposed on a cathode current collector, the cathode material and the cathode current collector forming a cathode. The electrochemical cell further includes a first separator disposed on the anode, a second separator disposed on the cathode, and an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material, the interlayer including a source of lithium ions, the lithium ions configured to migrate toward the anode upon a voltage difference between the interlayer and the anode exceeding a threshold value. In some embodiments, the anode can include an anode material disposed on an anode current collector. In some embodiments, the anode material can include graphite, silicon, and / or hard carbon.

The invention relates to a method and a system for simultaneously acquiring complete form and omics molecular information of a single neuron. The method comprises the following steps: acquiring fluorescently-labeled samples of cell bodies, dendrites and axons of the neuron; performing cyclic operation of scanning imaging and cutting on the section of the sample until the scanning imaging of the whole sample is completed, and collecting a section containing a fluorescence-labeled neuron cell body obtained by cutting; the method comprises the following steps: reconstructing a sample section three-dimensional image obtained based on scanning imaging operation to obtain a complete form of neurons, extracting fluorescently-labeled neuronal cell bodies from collected slices, and obtaining omics molecular information of the neurons through omics analysis. According to the method, the fine and complete form and omics molecular information of the same neuron can be effectively integrated, and the problem that the two kinds of key information cannot be obtained at the same time at the single neuron precision level is successfully solved.

The invention discloses a personalized precise fitness scheme intelligent pushing method and system, and relates to the technical field of intelligent fitness, and the method comprises the steps: collecting motion data of a user in real time, and carrying out the preprocessing; the method comprises the following steps: collecting a fitness target of a user, converting the fitness target into a target vector, activating a task sub-network in a dendritic neural network according to a matching degree between motion data of the user and the target vector, dynamically adjusting weights and importance of different tasks in the task sub-network through an attention mechanism, and generating and optimizing a preliminary fitness scheme through multiple agents. The most relevant sub-networks are activated in real time, task priorities are adjusted through an attention mechanism to adapt to environment changes and user states, the exercise intensity is optimized through fuzzy logic reasoning, training tasks are automatically adjusted according to real-time feedback of users, the balance between the tasks is optimized through co-evolution between agents, and the training efficiency is improved. The personalized fitness scheme can be continuously optimized, and more accurate exercise recommendation is provided under the dynamic environment and user demand changes.

The invention relates to the technical field of new energy system fault diagnosis, in particular to a solar cell coupling hydrogen production system fault diagnosis method based on big data, and the method comprises the steps: collecting photovoltaic, electrolytic cell and control unit multi-source heterogeneous data, and detecting the abnormality through an abnormality detection core model; matching and repairing by combining historical similar sections to obtain operation re-repairing data; a multi-scale expansion convolutional neural network is adopted to extract time sequence fault features, a backbone network is adopted to extract infrared image high-order features, and heterogeneous aggregation features are obtained through fusion of a spiking neuron model and virtual dendritic branches; constructing dynamic graph nodes and attributes according to features and components, and integrating multiple indexes to fit a causal association strength weight; and multi-link diagnosis: obtaining a fault type through a quantum annealing algorithm, positioning a fault through causal discovery and a virtual dry prediction algorithm, integrating and reporting to a server. The method can improve the fault diagnosis accuracy and real-time performance, and is suitable for fault monitoring of the solar hydrogen production system.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

Provided herein are tetracyclic heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

The invention relates to the technical field of antitumor drugs, in particular to a Ru (II) complex and a preparation method and application thereof, and the Ru (II) complex has a structure as shown in a formula I. The Ru (II) complex synthesized by the method disclosed by the invention not only has relatively high cytotoxicity, but also has good photodynamic antitumor activity. After the complex is illuminated, the efficiency of the complex entering cells in an active transportation mode can be accelerated, mitochondria and endoplasmic reticulum are targeted at the same time, mitochondrial membrane potential decline and endoplasmic reticulum stress are caused to form a dual organelle damage effect, immunogenic cell death is caused, the tumor microenvironment is adjusted, and the tumor cell immunogenicity is improved. The enrichment of dendritic cells (DCs) in tumor cells is realized, the chemotactic activity of effector T cells is improved, the proportion of CD4 < + > and Foxp3 < + > cell populations is reduced, and finally the anti-tumor immune response is activated. Meanwhile, the complex provided by the invention can also induce the cell to generate pan apoptosis, retard the cell cycle in the G2 / M period and enhance the effect of the complex in inhibiting tumor proliferation.

Provided herein are tetracyclic heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

There is provided an improved neuron model for spiking neural networks. The neuron model comprises somatic synapses as well as dendritic synapses. The somatic synapses are used for receiving an input token, and the dendritic synapses are used for receiving contextual data. The contextual data is used to modulate the behavior of the spiking neuron. The neuron model may be used to implement an attention mechanism in SSNs and to implement a Mixture-of-Experts architecture.

The invention belongs to the field of medicines, and discloses application of a stress-induced stem cell extract in treatment of cerebral apoplexy. The inventor finds that stem cells are cultured under proper stress conditions through screening, and the separated stem cell extract (also known as Alritoin) can increase the axon length and dendritic length of normal primary neurons and is beneficial to growth and conduction of nerve fibers; in a pdMCAO model, the volume of cerebral infarction in the acute stage of ischemia of a mouse can be remarkably reduced, the neurological function score can be improved, and a relatively good improvement trend is achieved in the aspect of cognition; in the acute stage of cerebral ischemia reperfusion, the pharmaceutical composition has remarkable effects on reducing the cerebral infarction volume of a mouse, reducing relative edema and improving the neurological function, and is relatively long in medication time window; in a cerebral ischemia reperfusion model, the trend of improving local cerebral blood flow is shown. The allitoin is expected to be developed into a promising drug for cerebral apoplexy, especially a drug for treating ischemic cerebral apoplexy.

The invention discloses a pulse neural network lightweight method based on nonlinear pruning, and relates to the technical field of artificial intelligence and neural networks. The method comprises the following steps: S1, constructing an NDI-LIF spiking neural network model, and introducing a bilinear product term into an input current in a dynamic updating process of a neuron membrane potential; s2, constructing a nonlinear synaptic pruning mechanism, representing a connection weight as a re-parameterization function composed of a re-parameterization weight and a conversion gain coefficient, and pruning the connection weight based on the re-parameterization function; and S3, training the NSPDI-SNN model to obtain a lightweight pulse neural network. By introducing a nonlinear dendritic integration mechanism and a state-adjustable synaptic pruning mechanism, balance between network sparsity and high performance is realized while the expression ability of the model is enhanced, and a lightweight spiking neural network model with high spatial-temporal expression ability, highly sparse structure and reasonable biological mechanism is constructed. And the generalization ability and the efficient training performance under various tasks are ensured.

The invention discloses a polyethylene glycol modified gold and manganese dioxide nano particle and a preparation method and application thereof, and belongs to the technical field of biological medicine, the polyethylene glycol modified gold and manganese dioxide nano particle (GMCN and PEG) has good biocompatibility under neutral physiological conditions, can relieve tumor hypoxia and increase generation of active oxygen in acidic TME, and has a good anti-tumor effect. The radiotherapy sensitivity is improved; and immune cell death is induced. Meanwhile, a cGAS-STING signal channel can be activated, dendritic cell maturation, macrophage M1 polarization and T cell infiltration are promoted, and the immunosuppression state in TME is counteracted. In addition, the GMCN-coated PEG also has an MR-CT bimodal imaging enhancement function, and integration of diagnosis and treatment is realized. The nano sensitizer disclosed by the invention has huge potential in the aspects of improving the radiotherapy curative effect, remodeling the tumor microenvironment, promoting the anti-tumor immunity, enhancing the biomedical imaging and the like.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

The invention discloses a glucan modified bionic nanoparticle as well as a preparation method and application thereof. Preparing nanoparticles based on PLGA as an inner core; the tumor cell membrane is extracted from B16F10 melanoma cells and is used as an outer capsid; glucan is coupled with a hydrophobic long chain through reductive amination and is modified on the surface of a biomimetic nanoparticle cell membrane through a hydrophobic effect. The dextran nano delivery system is successfully constructed, cell membrane specific antigens and dextran are efficiently and jointly delivered to lymph nodes, tumor cell membranes provide epitopes for immune activation of nanoparticles, and beta-dextran provides molecular support for nanoparticle targeting immune cells. In-vivo and in-vitro activity experiments prove that the glycolipid modified bionic nanoparticles can effectively activate innate immunity through macrophages and NK cells, can promote dendritic cell antigen presentation, and initiate potent adaptive immune response. The bionic nanoparticles have huge development potential of novel tumor vaccines, and a new thought is provided for immunotherapy of cancers.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

The invention relates to the technical field of brain science image processing, and discloses a brain tissue neuronal morphology three-dimensional reconstruction and connection group analysis method and system, and the method comprises the steps: carrying out the feature point extraction and matching and optical flow registration of continuous ultrathin section electron microscope images, and obtaining three-dimensional image volume data; carrying out semantic segmentation on cell bodies, dendrites, axons and dendritic spines through a three-dimensional deep convolutional neural network, and driving secondary registration through confidence feedback; detecting synapses and classifying the synapses as excitatory or inhibitory types; executing topology perception skeletonized reconstruction and performing segmentation correction through topology anomaly feedback constraint; and constructing a synaptic connection matrix and executing graph theory analysis.

The invention discloses a polar diaphragm optimization method based on a high-fidelity electrochemical-phase field model, which comprises the following steps: constructing a high-fidelity electrochemical-phase field model considering a diaphragm substrate and a polar coating to describe the growth behavior of lithium dendrites in the electrodeposition process of a lithium battery; collecting physical property parameters of the diaphragm matrix and the polar coating, substituting the physical property parameters into the model, establishing a computational domain and performing grid division; carrying out numerical solution on the model by utilizing a finite difference method to obtain growth morphology data of the lithium dendrites on the surface of the anode; and performing quantitative characterization on dendritic crystal morphology uniformity based on the growth morphology data to obtain dendritic crystal indexes, adjusting diaphragm physical property parameters according to the indexes, and repeating simulation iteration to optimize the diaphragm structure. By introducing multi-phase field sequence parameters and comprehensively describing the influence of the diaphragm matrix and the polar coating on lithium ion transmission, electrochemical reaction and interface characteristics, the high-precision simulation and optimization of the polar diaphragm design are realized, and the growth of lithium dendrites can be effectively inhibited.

The invention belongs to the technical field of immune effect drugs, and discloses a dendritic cell albumin suspension and a preparation method and application thereof.The preparation method of the dendritic cell albumin suspension includes the following steps that isolated mononuclear cells PBMC are collected, and matured DCs are cultured in a laminar flow purification laboratory; loading the multi-valence hepatitis B virus antigen epitope peptide on the DC; and the DC cell albumin suspension is prepared. The CTL immune effect excited by the DC can effectively remove HBV viruses in an integrated state in liver cells, so that the conditions of patients with hepatitis B and cirrhosis are reversed until HBV antigens are negative, and the conditions are relieved fundamentally; in the immune response excited by DC, the effector CTL cells immediately play a role in clearing HBV viruses, and the memory T lymphocytes play a role in clearing HBV viruses in vivo for a long time, so that the condition of hepatitis B is continuously reversed. Reagents used in the DC culture process are completely localized. The cost is greatly reduced and is obviously lower than that of foreign countries, and popularization is facilitated; china gets rid of the history of long-term dependence on imported anti-hepatitis B viruses.

The invention discloses a fruit image classification method based on a wide area network dendritic neuron model, and the method comprises the steps: achieving the multi-scale feature extraction through parallel 1 * 1, 3 * 3 and 5 * 5 convolution and pooling branches, carrying out the fusion convolution, LeCannTanh activation and batch normalization, generating a feature representation through the combination of global average pooling and a lightweight feedforward network, and carrying out the classification of fruit images through the feature representation. And self-adaptive nonlinear classification is realized by means of synaptic-dendritic-somatic cell-axon hierarchical processing of dynamic dendritic neurons. Experimental results show that the method has the advantages of high precision, high robustness and low time delay in scenes with complex backgrounds, large intra-class differences and small samples, and is suitable for industrial applications such as intelligent sorting and automatic quality inspection.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention discloses an anti-tumor pharmaceutical composition based on NBDHEX and application of the anti-tumor pharmaceutical composition in treatment of immunosuppressive malignant tumors. The pharmaceutical composition comprises NBDHEX (6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio) hexanol) and a PD-1 (programmed death-1) inhibitor, and is characterized in that the NBDHEX (6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio) hexanol) and the PD-1 inhibitor are used as raw materials. The NBDHEX can induce tumor cells to generate immunogenic death and promote tumor antigen release, DAMPs signal activation and dendritic cell maturation, so that an immunosuppressive tumor microenvironment is remodeled, and CD8 + T cell infiltration and effector functions are enhanced. The pharmaceutical composition can significantly improve the anti-tumor immune response intensity and the treatment response rate. Animal experiments and cell experiments verify the synergistic anti-tumor effect of the composition in a lymphoma model. The immunosuppressive malignant tumors are suitable for treatment of various immunosuppressive malignant tumors including lymphoma, and are especially suitable for patients with poor single-drug reaction or drug resistance to immune checkpoint inhibitors, and a new way is provided for clinical treatment of tumors.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

The invention discloses a novel immunologic adjuvant, a composition containing the immunologic adjuvant and a pharmaceutical composition. The immunologic adjuvant is picrasidine S. The immunologic adjuvant composition comprises picrasidine S and optionally one or more other types of immunologic adjuvants, such as an aluminum adjuvant. The pharmaceutical composition comprises an antigen and the immunologic adjuvant composition. Experiments prove that the picrasidine S can effectively stimulate dendritic cells to generate cell factors IFN-beta and IL-6, and has PS dose dependence; picrasidine S plays an important role in enhancing specific humoral immune response of different types of antigens, and has a stronger effect than an aluminum adjuvant; the picrasidine S immunity can enhance the anti-tumor immune response in different tumor models. According to the invention, a new candidate drug is provided for research and development of a new generation of vaccine adjuvants, and meanwhile, the medical application of the picrasidine S is also widened.

The invention discloses a PD-L1 / TGF-beta / STING triple targeting antibody coupling drug as well as a preparation method and application thereof, and belongs to the field of tumor immunotherapy. The ADC structure is Ab-[L-D] n, Ab is a bispecific antibody YM101 targeting PD-L1 and TGF-beta, L is a cleavable connexon, and D is an STING agonist. The preparation method comprises the following steps: carrier molecule deprotection, linker functionalization, linker-load coupling, antibody sulfhydrylation modification, coupling reaction and affinity chromatography purification. The ADC can increase the number of CXCL16 < + > macrophages, dendritic cells and CXCR6 < + > T cells infiltrated in tumors, effectively reverses the drug resistance of a TGF-beta * PD-L1 bispecific antibody, has a strong anti-tumor effect and no obvious toxic or side effect, and has a good application prospect in preparation of anti-tumor drugs.

The present invention relates to a complex comprising a polysaccharide conjugate, an anti-PD-L1 monoclonal antibody, and a PKM2 inhibitor. The complex of the present invention can accumulate and remain in tumor tissue, effectively stimulate dendritic cell maturation, alleviate the inhibitory immune microenvironment, and trigger a specific anti-tumor immune response. It can effectively inhibit the expression of PKM2, thereby inhibiting glycolysis in tumor tissue and providing a more favorable environment for T lymphocytes to infiltrate tumor tissue. The complex of the present invention is expected to enhance the therapeutic effect of RFA on patients with advanced HCC by reprogramming iRFA-induced tumor immunosuppression, and has great potential in improving the prognosis of patients with advanced HCC treated with RFA.